New England Regional Coordinating Center for the NINDS Stroke Trials Network

我们建议继续新英格兰区域协调中心(NERCC)，这是一个综合团队， 波士顿和马萨诸塞州西部的医院和EMS机构，将作为顶级注册网站和 NINDS中风试验网络充满活力的贡献者。我们的小组包括许多主要的成人学者 大波士顿地区的中风中心，我们30多家医院新英格兰TeleStroke转诊网络将 进一步扩大我们潜在的招聘范围。所有核心医院都有经过证明的成功记录 临床试验的管理和执行。特别是，所有的医院都有既定的研究 在中风神经病学方面进行持续临床研究的基础设施，并与 纪律。首席研究员Lee H.Schwamm医学博士和联合调查员带来了一组互补的 管理成功的转化性临床研究项目的技能，指导委员会的成员资格， 以及各自领域的国家领导地位。我们的团队包括经验丰富的血管临床研究人员 神经学、急诊医学、神经血管内科学、神经外科、神经重症监护、神经成像、中风 康复，以及成人和儿童的临床前基础和转化性中风调查。优势 NERCC团队的成员包括1)多名调查人员之间密切的个人和专业联系；2)大型 来自大都市地区不同医院环境的患者人数；3)现场的人才团队 在多中心拥有科学成就、创新和学科招募记录的调查人员 试验；4)现有的NINDS资助的研究和临床试验管理基础设施；5)现有的临床 研究项目，如神经学临床研究所，NIH临床和翻译科学奖 波士顿大学和哈佛大学的项目；SIREN和NeuroNEXT临床协调网站 中心。总体而言，NERCC团队在第一个月表现出了出色的承诺和表现 StrokeNet周期，并有资源、远见和热情继续开发新的翻译 科学并成功执行NINDS StrokeNet阶段1、2和3试验。

We propose to continue the New England Regional Coordinating Center (NERCC), an integrated team of hospitals and EMS agencies in Boston and Western Massachusetts that will serve as a top-enrolling site and vibrant contributor to the NINDS Stroke Trials Network. Our group includes many of the major adult academic stroke centers in the Greater Boston area, and our 30+ hospital New England TeleStroke referral network will extend our potential recruitment even further. All core hospitals have a proven track record of successful management and performance of clinical trials. In particular, all hospitals have an established research infrastructure that performs ongoing clinical research in stroke neurology with strong collaborations across disciplines. Principal investigator Lee H. Schwamm, MD, and Co-Investigators bring a complementary set of skills in managing successful translational clinical research programs, membership on Steering Committees, and positions of national leadership in their fields. Our team includes seasoned clinical investigators in vascular neurology, emergency medicine, neuroendovascular, neurosurgery, neurointensive care, neuroimaging, stroke rehabilitation, and preclinical basic and translational stroke investigation in both adults and children. Strengths of the NERCC team include 1) close personal and professional ties between multiple investigators; 2) large patient population from diverse hospital settings in a major metropolitan area; 3) talented teams of site investigators with track records of scientific achievement, innovation, and subject recruitment in multicenter trials; 4) robust existing NINDS-funded research and clinical trial management infrastructure; 5) existing clinical research programs, e.g., Neurology Clinical Research Institute, NIH Clinical and Translational Science Award programs at Boston University and across Harvard; Sites in the SIREN and NeuroNEXT Clinical Coordinating Center. Overall, the NERCC Team has demonstrated outstanding commitment and performance in the first StrokeNet cycle, and has the resources, vision, and enthusiasm to continue to develop new translational science and successfully execute the NINDS StrokeNet Phase 1,2 and 3 trials.